GeoVax Advances GEO-MVA Toward Pivotal Phase 3 Study ImplementationSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Initiates Global Health Outreach to WHO, Africa CDC and Other Agencies Regarding Ebola Vaccine Portfolio Amid Expanding OutbreakSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Applauds Clinical Validation of Combination Immunotherapy StrategiesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Chairman and CEO David Dodd to Participate in 2026 Georgia Life Sciences SummitSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights Capabilities Amid Congo's Expanding Ebola OutbreakSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights Gedeptin(R) Tumor-Priming Strategy as Immuno-Oncology Enters New PhaseSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Announces Completion of Key GEO-MVA Development Milestones, Positioning Program for Pivotal Phase 3 Clinical StudySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Reports Second Quarter 2026 Financial Results and Provides Business UpdateSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights Strategic Alignment of GEO-MVA With HHS/ASPR's Five-Year Medical Countermeasure Preparedness StrategySearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine ReadinessSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights Continued U.S. Government Investment in Orthopox Preparedness as Strategic Validation of Long-Term Vaccine ReadinessRecent Federal Procurement Reinforces the Importance of Sustained Investment in Domestic Vaccine Manufacturing and Diversified Medical Countermeasures
GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant CancersSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant CancersRecent Publication and Growing Industry Focus on Immune-Priming Strategies Support Continued Evaluation of Gedeptin® as a Potential Complement to Checkpoint Inhibitor Therapy
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy ResponsesSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy ResponsesPublication Highlights Potential for Intratumoral Gedeptin® Therapy to Enhance Checkpoint Inhibitor Responses and Activate Systemic Anti-Tumor Immunity
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease InnovationSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax CEO Highlights Renewed Strategic Interest in Vaccine Platforms and Infectious Disease InnovationRecent Industry Activity Reinforces the Need for Manufacturing Resilience, Diversified Vaccine Supply, and Health Security Amid an Evolving Global Biothreat Landscape
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat ReadinessSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
GeoVax CEO Welcomes FIFA World Cup 2026 While Addressing Biothreat ReadinessLargest FIFA Tournament in History Expected to Draw 6.5 Million Attendees Across North America and More Than 1.2 Million International Visitors to U.S. Host Cities Amid Growing Concerns Regarding Mpox, Ebola, Hantavirus, Measles, and Other Emerging Infectious Disease Threats
